FDA Grants Breakthrough Approval for LungFX, a Novel Ex Vivo Lung Perfusion Device

Lung Bioengineering, a subsidiary of United Therapeutics (UTHR), has secured Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for LungFX, its ex vivo assessment device for lung transplantation. This marks the first FDA-approved centralized ex vivo lung perfusion (EVLP) platform for evaluating donor lungs outside the body. The approval is based on clinical safety and efficacy data gathered through the Centralized Lung Evaluation System (CLES), despite the clinical trial not fully meeting its primary endpoint of 12-month survival, representing a regulatory milestone achieved under limited indications.

Addressing Organ Wastage and the Clinical Need for Advanced Perfusion Technology

Currently, over 80% of donor lungs in the United States are deemed unsuitable and discarded, leading to a critical shortage of organs for transplantation. LungFX is designed to perfuse and maintain the physiological state of these unused lungs at normothermic temperatures, allowing for detailed ex vivo assessment. Although the CLES Pivotal Study showed higher 12-month mortality and graft loss rates in the LungFX group compared to the non-EVLP control group, the device is recognized as the only means to assess and potentially expand the use of marginal organs, which would otherwise be discarded due to not meeting standard matching criteria.

Launching a Centralized Service in 2027 and Strengthening Market Position

United Therapeutics plans to launch the LungFX service through its Lung Bioengineering subsidiary, utilizing its Silver Spring and Jacksonville centers, starting in 2027. This centralized business model allows individual hospitals and transplant centers to access real-time organ viability data through OrganVue, a remote organ assessment software, without the need for expensive EVLP equipment and dedicated personnel. This differentiates it from competitors like TransMedics' OCS Lung and XVIVO Perfusion's XPS system, which focus on hardware sales to individual transplant centers, positioning LungFX as a high-margin, service-based business model.

Strategic Investment in Expanding the Lung Transplantation Ecosystem

With the approval of LungFX, United Therapeutics is further solidifying its transformation from a pharmaceutical company to a biomedical organ supply platform company. In the global ex vivo organ preservation and transplantation market, estimated at USD 600 million, LungFX is expected to be a powerful tool for addressing the unmet needs in the lung transplantation segment. Although initial adoption may be slower due to the mixed results in the CLES clinical trial, the combination of Lung Bioengineering's infrastructure, with over 1,100 EVLP procedures performed and over 600 successful lung transplants, is expected to drive long-term market dominance and revenue growth.